alliReport

Free! Join

Discussions
Your INDEPENDENT source of news about the new diet drug alli (low-dose Xenical)
 
alli News from February 2007 -- News About Low-Dose Xenical
 
alli Report Launches Discussion Forum for users of Diet Drug alli / Xenical / Orlistat
 

With a growing number of overweight individuals hoping to soon obtain weight-loss pill alli, and GlaxoSmithKline already offering an assortment of dietary tips and exercise advise, the alli Report has launched a discussion forum to enable readers to report on their weight-loss results, side-effects, and experiences.

"We decided to start the Alli Report Forum after receiving a growing volume of email from patients -- many of whom have taken prescription Xenical, Meridia or other diet drugs -- who are anxious to compare experiences with others," said publisher Milton R. Benjamin.

"While the alli Report's primary mission will continue to be to report on the regulatory process and issues involved in the approval and marketing of this highly anticipated diet drug, our reporting staff will now be augmented by hundreds of orlistat users reporting on their own experiences," he added.

Five months ago, the alli Report's sister site, the Acomplia Report, launched a similar forum, and hundreds of users of the weight-loss drug -- as well as physicians in both Europe and the United States -- have registered to participate in discussions on the site.

That forum is prompting the liveliest exchange of information on rimonabant found on the Internet.

"We are very hopeful that the alli Report Forum will attract users seriously interested in the use of this highly anticipated drug to treat a serious medical condition, and that the forum will become an important resource for the exchange of helpful and potentially life-transforming information," Benjamin said.

 
 
 
 
 

 

Other Diet Resources
Privacy Policy | Terms and Disclaimers | About the alli Report
Click to VerifyWe subscribe to the HONcode principles of the HON Foundation.
This is an independent news site reporting on alli, a half-strength version of the diet drug Xenical (orlistat), which GlaxoSmithKlein hopes to market under the trademarked name alli. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided is for informational purposes only. Always consult a doctor or medical professional with questions regarding a medical condition.

Last Updated: 02/09/2007 Copyright 2004-2006 Medical Week News, Inc. All Rights Reserved